Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

MabVax Therapeutics

Request full access

Biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies

San Diego, United StatesFounded 2006Biotech & Life Sciences

About MabVax Therapeutics

MabVax Therapeutics (Nasdaq: MBVX) is a clinical-stage biotechnology company specializing in the discovery and rapid clinical development of fully human antibodies aimed at addressing unmet medical needs in cancer treatment. The company's core product, MVT-5873, is a fully human IgG1 monoclonal antibody targeting sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials for pancreatic cancer and other CA19-9 positive tumors. MabVax collaborates with renowned institutions such as Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health, and Imaging Endpoints. To date, 50 patients have been treated with either MVT-5873 or the PET imaging diagnostic product MVT-2163 in Phase 1 clinical studies, demonstrating early safety, target specificity, and potential efficacy. The company has also commenced patient dosing for its radioimmunotherapy product MVT-1075 in a Phase 1 clinical study. MabVax operates in the biotechnology sector, primarily serving the oncology market, and generates revenue through the development and potential commercialization of its antibody-based therapies.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2014

MabVax Therapeutics in the San Diego ecosystem

Live from Dealroom

The MabVax Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Biomark Capital
  • Numoda Capital Innovations
  • Burrill

Series B and later2 investors entered at this stage

  • Boehringer Ingelheim
  • TRITON FUNDS
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about MabVax Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MabVax Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.